Misagh Karimi, M.D.
I think it's important to make a connection ... to make sure the patient feels comfortable.
Misagh Karimi, M.D., a physician with two decades' experience, says he chose oncology because it's a fast-paced, constantly-evolving field with many exciting new developments. As of 2020, Dr. Karimi has relocated to City of Hope's Newport Beach Clinic.
Born in Iran, Dr. Karimi immigrated to the U.S. and received a bachelor's degree at University of California Berkeley. He earned his medical degree at George Washington University and spent nearly a decade at University of California Irvine as an intern, resident, physician, researcher and instructor. After two years at Oregon's Knight Cancer Institute, Dr. Karimi returned to Southern California to join the Wilshire Oncology Medical Group, which became City of Hope's Corona location. As of 2020, Dr. Karimi relocated to City of Hope's Newport Beach community practice site.
Dr. Karimi is passionate about patient education, appearing frequently at community forums to discuss obesity, the environment and other possible risk factors for cancer.
2004, American Board of Internal Medicine – Hematology
2003, American Board of Internal Medicine – Medical Oncology
1999, American Board of Internal Medicine
1996, Doctor of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia
1992, Bachelor of Arts, Molecular Genetics, University of California, Berkeley
2001-2002, Research Fellowship, Hematology/Oncology, University of California Irvine College of Medicine
2000-2003, Clinical Fellowship, Hematology/Oncology, University of California Irvine College of Medicine
1999-2000, Chief Resident, Department of Medicine, University of California Irvine College of Medicine
1997-1999, Internal Medicine, University of California Irvine College of Medicine
1996-1997, Internal Medicine, University of California Irvine College of Medicine
2020-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Newport Beach, California
2014-2020, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Corona, California
2011-2014, Medical Oncologist, Hematologist Wilshire Oncology Medical Group, La Verne, California
2008-2010, Assistant Professor, Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon
2008-2010, Department Head, Community Hematology Oncology Clinical Research, Knight Cancer Institute, Oregon Health and Science University, Beaverton, Oregon
2005-2008, Medical Oncologist-Hematologist, Pacific Oncology, Beaverton, Oregon
2003-2005, Assistant Professor and Hematology Oncology Coordinator, Gastrointestinal Cancer Program, University of California, Irvine Medical Center, Orange, California
1995, First Prize, Annual Medical School Research Presentation
Beaumont Society, Washington, DC1994, Gill Summer Fellowship Award, The George Washington University School of Medicine and Health Sciences, Washington, DC
1993-1996, Horowitz Scholarship, The George Washington University Medical Center, Washington, DC
2005-2009, Member, Columbia River Oncology Program
2003-present, Member, Southwest Oncology Group, GI Subcommittee
2002-present, Member, American Society of Hematology
2001-present, Member, American Association for Cancer Research
2000-present, Member, American Society of Clinical Oncology
1999-2000, Associate, American College of Physicians
1992-1996, Member, American Medical Student Association
- Karimi M, Manning F, Patierno S. Induction of Apoptotic Cell Death by Brefeldin A in Human and Hamster Cells. Proc. Am. Association for Cancer Research, 36:36, 1995.
- Karimi M, Buckmeir J, Milivanovic T, Brodhag T, Holcombe RF. Effect of Interleukin-18 & Levamisole on NFkB Expression In Jurkat Cells. J Investigational Medicine 47: 99A, 1999.
- Karimi M, Byun T, Milovanovic T, Lin F, Waterman M, Marsh JL, Holcombe RF. Graded expression of frizzled-inhibitory proteins in gastrointestinal tissues: Potential role in stem cell homeostasis. Proc. Am. Association for Cancer Research, 44:1193, 2003.
- Timothy B, Karimi M, Marsh JL, Milovanovic1 T, Lin F, Holcombe RF. Expression of Secreted Wnt Antagonist in Gastrointestinal Tissues: Potential Role in Stem Cell Homeostasis Journal of Clinical Pathology: Molecular Pathology.
Are generic multisource (generic) chemotherapy (CT) drugs as effective as proprietary single-source (proprietary) drugs: Evidence from in vitro CT-induced apoptosis (APOP) in non-small cell lung cancer (NSCLC), colorectal cancer (Colon CA) compared to recurrent/metastatic breast carcinoma (Breast CA)
Karimi M, Rajurkar SP, Bosserman LD, Rogers K, Davidson DC, Willis CR, Rutledge J, Hallquist A, Presant CA. J Clin Oncol 30, 2012 (suppl; abstr e13003)
Patterns of in vitro chemotherapy (CT)-induced apoptosis (APOP) in recurrent/metastatic breast carcinoma (CA): Comparisons of generic multisource drugs (generics) with proprietary single-source drugs (proprietaries)
Bosserman LD, Rogers K, Davidson DC, Willis CR, Rutledge J, Hallquist A, Young T, Rajurkar SP, Karimi M, Presant CA. J Clin Oncol 30, 2012 (suppl; abstr e11562)
Integrating Academic and Community Practices in the management of Colorectal Cancer: The City of Hope Model
Karimi M 1, Wang C 1, Bahadini B 2, Hajjar G 2, Fakih M 1,*
- Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; mkarimi@coh.org (M.K.); chowang@coh.org (C.W.)
- Department of Medical Oncology and Hematology, City of Hope National Medical Center, Mission Hills, CA 91345, USA; bbahadini@coh.org (B.B.); ghajjar@coh.org (G.H.) Journal of Clinical Medicine Review: 2 June 2020
Radiomic features of renal cell carcinoma metastatic sites can predict BAP1 mutation.
Meza L, Filippov A, Zengin Z, Naimb S, Dizman N, Chehrazi- Raffle A, Philip E, Malhotraa J, Muddasani R, Chawla N, Salgia S, Reddy K, Karimi M, et al. Presented at the International Kidney Cancer Symposium: A Virtual Experience. November, 2020.
Use of Molecular Assays and Circulating Tumor DNA in Early Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group (GICTEG)
Loaiza-Bonilla A, Benson AB, Grothey A, Karimi M, Klepner SJ, Lin D, Mahtani R, Soares HP. Oncologist. 2021 Mar 2. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/33650740/